Aethon Therapeutics
Christoph Rader is a seasoned expert in biochemistry, molecular biology, and immunology, currently serving as Chief Technology Officer at Aethon Therapeutics since March 2023. Rader's extensive academic background includes professorships at the Scripps Research and the University of Florida, where contributions were made to the fields of cancer biology, immunology, and biotechnology. Rader has also held advisory roles at several biotechnology firms, including RiverVest Venture Partners, Pyxis Oncology, T-CURX GmbH, and NBE-Therapeutics AG, focusing on antibody-drug conjugates and CAR-T therapies. Rader's previous experience includes a significant tenure as a Senior Scientist at the National Cancer Institute and an academic career that began as an Assistant Professor at Scripps Research. Educational qualifications include a PhD and MS from the University of Zurich, and a BS from the University of Bayreuth.
This person is not in any teams
This person is not in any offices
Aethon Therapeutics
Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations.